Climb Bio Inc., a clinical stage biotechnology company, reported its financial results for the first quarter ended March 31, 2025. The company revealed that its cash, cash equivalents, and marketable securities amounted to $197.8 million as of March 31, 2025, which are expected to support operations through 2027. Research and Development expenses significantly increased to $17.3 million in Q1 2025 from $1.1 million in the same period in 2024, largely due to a $9.0 million upfront payment to Mabworks as part of a license agreement. General and Administrative expenses also rose to $5.7 million from $1.9 million in the comparable period last year. Other income, net, was reported at $2.2 million, up from $1.3 million in Q1 2024. In terms of business updates, Climb Bio is advancing its clinical programs, with the initiation of clinical trials for budoprutug in Immune Thrombocytopenia $(ITP)$ and Systemic Lupus Erythematosus $(SLE)$ expected soon, and in Primary Membranous Nephropathy (pMN) in the second half of 2025. The company also anticipates submitting an IND or CTA for CLYM116 in the latter half of the year. New appointments include Kim Cobleigh Drapkin, CPA, and Bo Cumbo as Independent Directors, with Perrin Wilson, Ph.D., joining as Chief Business Officer.